Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review. Int J Gynecol Cancer. 2018 May;20(4):738-48. doi: 10.1097/IGC.0000000000001222
Bernfort L, Brodtkorb T. QALY som effektmått inom vården : möjligheter och begränsningar. Linköping: linköping University Electronic Press. Cmt- Rapport. 2012.
Brodtkorb T. National system for assessment, prioritization and introduction of non-pharmaceutical health technologies, a pilot study. Cmt- Rapport. 2010.
Alverez SA, Bae-Jump V, Havrilesky LJ, Calingaert B, Clarke-Pearson ADL, Soper JT, Gehrig PA. Attitudes regarding the use of hematopoietic colony-stimulating factor utilization and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer. 2009 Apr;19(3):447-54.
Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A. High expression of insulin-like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006 Jul 1;16(4):1529-35.
Williams LK, Pladevall-Vila M, Fendrick AM, Lafata JE, McMahon LF. Differences in the reporting of care-related patient injuries to existing reporting systems. Jt Comm J Qual Patient Saf. 2003 Sep;29(9):460-7.
Smart JD, Nicholls TJ, Green KL, Rogers DJ, Cook JD, Wolowacz SE. Lectins in drug delivery: an in vivo toxicity study of the lectins from Solanum tuberosum and Helix pomatia. J Pharm Pharmacol. 1998 Sep.
Nicholls TJ, Cook DJ, Rogers DJ, Wolowacz SE, Smart JD. An investigation of lectin binding sites within the precorneal region. J Pharm Pharmacol. 1994;46:1050.